Abstract
Clinical data suggested that a regimen incorporating doxorubicin to 5-fluorouracil (5-FU) and cisplatin may be more effective but probably quite toxic for advanced gastric cancer patients. With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, cisplatin and pegylated liposomal doxorubicin with a combination of 5-FU, cisplatin and mitomycin-C. Seventy-eight patients were randomised to receive 5-FU (400mg/m(2) bolus, 600mg/m(2) 22h continuous infusion day 1 and 2) and cisplatin (50mg/m(2) day 1) every 2weeks, combined either with pegylated liposomal doxorubicin (20mg/m(2) day 1 every two weeks) (arm A) or mitomycin-C (7mg/m(2) every 6weeks) (arm B). The overall response rate was 64.1% in arm A and 38.5% in arm B (P=0.041). The median time to tumour progression and overall survival were 7.93 and 5.14months (P=0.04) and 12.1 and 8.3months (P=0.02) in arm A and B, respectively. Fourteen patients in arm A and 18 patients in arm B experienced a grade 3/4 toxic effect. A combination of pegylated liposomal doxorubicin, cisplatin and 5-FU can be safely administered in gastric cancer patients with a promising efficacy profile.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
